Unlocking the full potential of artificial intelligence requires these stakeholders to ensure their data are accessible and secure.
Inger Ødum Nielsen, Vanessa de Langsdorff, and John April
Advertisement
Articles by Inger Ødum Nielsen, Vanessa de Langsdorff, and John April
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Selective Safety Data and Visit Reduction, Protocol Design Execution Gaps, and China Trial Security Investigation
2
NEJM Retracts Tavneos Trial Paper as FDA, EMA Both Move to Pull Amgen Drug From Market
3
ACT Brief: Tavneos Trial Integrity Issues, Selective Safety Data Regulatory Pathways, and FDA PreCheck Program Launch
4
Protocol Design Doesn't Fail in the Protocol, It Fails in Transition to Trial
5